ApaTech steps up US synthetic bone graft drive
This article was originally published in Clinica
UK synthetic bone graft developer ApaTech is stepping up for the next stage in its own development with the establishment of US operations. The London, UK-based spin-out of Queen Mary University recently obtained FDA 510(k) clearance for its Pore-Si and ApaPore products, and is aiming to "capture significant market share in the US", according to ApaTech Inc's new president, Steve Czick.
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.